← All trials
NCT03800524
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2019
- Primary completion
- Jun 30, 2021
- Completion date
- Jun 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Humanitas Mirasole SpALead sponsor
- Katholieke Universiteit LeuvenCollaborator
- Utrecht UniversityCollaborator
- Sheffield Hallam UniversityCollaborator
- University of UlmCollaborator
- Trinity College DublinCollaborator
- University Hospital, ToursCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.